# US 11,026,994 B2 · Syndecan-2 compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,994 B2
- Document ID: US11026994B2
- Status: Granted
- Kind: B2
- Application number: 16/254,378
- Filed: 2019-01-22
- Published: 2019-12-05
- Granted: 2021-06-08
- Earliest claimed: 2013-04-16
- Assignees: Orbsen Therapeutics Limited
- Applicants: Orbsen Therapeutics Limited
- Inventors: Stephen Joseph Elliman
- Web page: https://patentgrep.com/patent/US11026994B2

## CPC

- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2039/505: {comprising antibodies}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

SDC2, compositions that comprise SDC2, vectors encoding SDC2 and compounds that modulate expression of SDC2 by cells are used for treatment of mammalian, e.g. human, cells to achieve immunomodulation or for other specific therapeutic interventions. Cells are treated by combining the cells with SDC2, treating the cells with an antibody or fragment thereof that binds SDC2 or modulating expression or activity of SDC2 by the cells. Cells or tissue are derived from treated cells for therapeutic uses based on their immunomodulatory or other therapeutic properties.

## Claims

### Claim 1

A method of reducing an inflammatory response in a subject, the method comprising contacting a cell of the subject with a composition comprising Syndecan-2 (SDC2) or a fragment of SDC2, wherein the SDC2 or the fragment of SDC2 has an anti-inflammatory effect.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fragment of SDC2 comprises at least 30 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

### Claim 3 (depends on 1)

The method of claim 1, wherein the SDC2 or fragment of SDC2 has a sequence with at least 90% identity to the amino acid sequence of SEQ ID NO: 3 over at least 30 consecutive residues.

### Claim 4 (depends on 1)

The method of claim 1, wherein the fragment of SDC2 comprises at least 61 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

### Claim 5 (depends on 1)

The method of claim 1, wherein the fragment of SDC2 comprises at least 79 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

### Claim 6 (depends on 1)

The method of claim 1, wherein the fragment of SDC2 comprises at least 87 consecutive residues of the amino acid sequence of SEQ ID NO: 3.

### Claim 7 (depends on 1)

The method of claim 1, wherein the SDC2 has the amino acid sequence of SEQ ID NO: 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the fragment of SDC2 is a polypeptide selected from the group consisting of residues 1-79; 1-87; 1-100; 1-144; 1-169; 9-79; 19-87; 19-100; 19-169; and 19-201 of a full-length SDC2.

### Claim 9 (depends on 1)

The method of claim 1, wherein the SDC2 is human SDC2.

### Claim 10 (depends on 1)

The method of claim 1, wherein the SDC2 or fragment of SDC2 is obtained from a cell culture supernatant.

### Claim 11 (depends on 1)

The method of claim 1, wherein the composition comprises a cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell comprises a stromal stem cell.

### Claim 13 (depends on 11)

The method of claim 11, wherein the cell comprises a nucleic acid encoding the SDC2 or fragment of SDC2.

### Claim 14 (depends on 11)

The method of claim 11, wherein the cell is transfected with a vector that encodes the SDC2 or fragment of SDC2.

### Claim 15 (depends on 11)

The method of claim 11, wherein the cell is infected with a virus that encodes the SDC2 or fragment of SDC2.

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition further comprises an anti-inflammatory agent selected from the group consisting of an anti-TNFα antibody, infliximab, adalimumab, certolizumab, golimumab, etanercept, an anti-CD3 antibody, muromonab-CD3, otelixizumab, teplizumab, visilizumab, and combinations thereof.

### Claim 17 (depends on 1)

The method of claim 1, wherein the SDC2 or fragment of SDC2 reduces at least one symptom of an inflammatory response in the subject.

### Claim 18 (depends on 1)

The method of claim 1, wherein the inflammatory response comprises a T cell proliferation response.

### Claim 19 (depends on 1)

The method of claim 1, wherein the inflammatory response comprises NFκB activation.

### Claim 20 (depends on 1)

The method of claim 1, wherein the inflammatory response comprises a response to at least one of Tumor Necrosis Factor-α (TNFα), Interleukin-6 (IL6), Interleukin-8 (IL8), and Interleukin-1β (IL1 (3).